Encephalitis
Recent clinical, regulatory, research and industry developments relating to this disease.
Neurodegeneration and the immune system: lessons from autoimmune encephalitis.
What we've learnt about autoimmune neurological diseases from neuropathology.
Converging synaptic and network dysfunctions in distinct autoimmune encephalitis.
Searching for Neuronal Antibodies in Psychiatric Diseases: Uncertain Findings and Implications.
Neuroinflammation and M2 microglia: the good, the bad, and the inflamed.
Multiple sclerosis: an immune or neurodegenerative disorder?
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q4 2026.
- Q4 2026A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
- Q4 2026Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
- Q3 2030Treatment With Dexamethasone in Patients With Tick-borne Encephalitis: Randomized Clinical Trial
Clinical MilestonesViewHide
- 2026-07-10A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisResults expected Q4 2026
- 2026-06-09Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune EncephalitisResults expected Q4 2026
- 2026-05-13Treatment With Dexamethasone in Patients With Tick-borne Encephalitis: Randomized Clinical TrialResults expected Q3 2030
- 2026-04-30Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence AreasPrimary completion
- 2026-07-10ClinicalA Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisResults expected Q4 2026
- 2026-06-09ClinicalSafety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune EncephalitisResults expected Q4 2026
- 2026-05-13ClinicalTreatment With Dexamethasone in Patients With Tick-borne Encephalitis: Randomized Clinical TrialResults expected Q3 2030
- 2026-04-30ClinicalMonitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence AreasPrimary completion
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Encephalitis6
- Hashimoto Disease3
- Autoimmune Diseases of the Nervous System2
- Alzheimer Disease1
- Anti-N-Methyl-D-Aspartate Receptor Encephalitis1
- Cognitive Dysfunction1
- High-Throughput Nucleotide Sequencing1
- Immune System1
Leading journals6
- Journal of neuroinflammation5
- The Journal of neuroscience : the official journal of the Society for Neuroscience2
- Acta neuropathologica1
- Alzheimer's & dementia : the journal of the Alzheimer's Association1
- Annual review of neuroscience1
- Brain : a journal of neurology1
Leading researchers8
- Höftberger R2
- Ahn J1
- Aisen PS1
- Alam A1
- Askwith C1
- Baltriukienė D1
- Beech W1
- Bénac N1
Affiliations (unnormalised)6
- Medical University of Vienna2
- University of California2
- Alzheimer's Therapeutic Research Institute (ATRI)1
- Beijing Fengtai Youanmen Hospital1
- Beijing Shijitan Hospital1
- Cardiac Electrophysiology Research and Training Center1
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Encephalitis is inflammation of the brain. The grounding describes it as arising from infection, autoimmune processes, toxins, and other conditions, with viral infection noted as a relatively frequent cause.
Supported causes include infection, autoimmune processes, toxins, and other conditions. Viral infections are described as a relatively frequent cause.
The literature grounding supports a neuroinflammatory process involving immune activation in the brain. It highlights cytokines, chemokines, autoantibodies, microglial activation states, and signal transduction as relevant to inflammatory injury and immune-mediated brain dysfunction.
The supplied grounding does not identify specific risk factors for encephalitis beyond its causes.
The supplied grounding does not provide treatment guidance for encephalitis. It only supports that the condition is studied in relation to neuroinflammation and immune-mediated mechanisms, not a specific standard treatment modality or drug class.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.